Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Hayes

Showing results (61-70 of 131) with videos related to

Pageof 14
Sort By:
Cancer Research|July 15, 1988
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancerC Tondini, D F Hayes, R Gelman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1992
Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptorL Damstrup, J Andersen, D W Kufe, et al.
Seminars in Oncology|March 1, 1987
New agents and new medical treatments for advanced breast cancerI C Henderson, D F Hayes, S Come, et al.
Cancer Research|February 15, 1990
Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrowC Tondini, S A Pap, D F Hayes, et al.
The Journal of Clinical Investigation|May 1, 1985
Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patientsD F Hayes, H Sekine, T Ohno, et al.
Cancer Research|May 1, 1992
Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigenL Perey, D F Hayes, P Maimonis, et al.
Cancer Research|May 19, 2001
Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibodyC Akewanlop, M Watanabe, B Singh, et al.
Archives of Surgery (Chicago, Ill. : 1960)|August 1, 1973
Early endoscopy. A guide to therapy for acute hemorrhage in the upper gastrointestinal tractC Sugawa, M H Werner, D F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study GroupC L Shapiro, T Ervin, L Welles, et al.
Breast Cancer Research and Treatment|June 16, 1999
Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210M Watanabe, P K Wallace, T Keler, et al.
Pageof 14

Showing results (61-70 of 131) with videos related to

Sort By:
Pageof 14
Cancer Research|July 15, 1988
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancerC Tondini, D F Hayes, R Gelman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1992
Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptorL Damstrup, J Andersen, D W Kufe, et al.
Seminars in Oncology|March 1, 1987
New agents and new medical treatments for advanced breast cancerI C Henderson, D F Hayes, S Come, et al.
Cancer Research|February 15, 1990
Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrowC Tondini, S A Pap, D F Hayes, et al.
The Journal of Clinical Investigation|May 1, 1985
Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patientsD F Hayes, H Sekine, T Ohno, et al.
Cancer Research|May 1, 1992
Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigenL Perey, D F Hayes, P Maimonis, et al.
Cancer Research|May 19, 2001
Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibodyC Akewanlop, M Watanabe, B Singh, et al.
Archives of Surgery (Chicago, Ill. : 1960)|August 1, 1973
Early endoscopy. A guide to therapy for acute hemorrhage in the upper gastrointestinal tractC Sugawa, M H Werner, D F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study GroupC L Shapiro, T Ervin, L Welles, et al.
Breast Cancer Research and Treatment|June 16, 1999
Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210M Watanabe, P K Wallace, T Keler, et al.
Pageof 14